ORGANOGENESIS HOLDINGS INC. Temporary Equity, Liquidation Preference
ORGANOGENESIS HOLDINGS INC. (ORGO) had Temporary Equity, Liquidation Preference of $147.96 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2026-08-06
- 2026-06-30: Temporary Equity, Liquidation Preference $147.96M.
- 2026-03-31: Temporary Equity, Liquidation Preference $145.06M.
- 2025-12-31: Temporary Equity, Liquidation Preference $142.22M.
- 2025-09-30: Temporary Equity, Liquidation Preference $139.43M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2026-06-30 | $147.96M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $145.06M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $142.22M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $139.43M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $136.69M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $134.01M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $131.39M 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |